Patients with inferior vena caval filters should receive chronic thromboprophylaxis

Medical Clinics of North America

Volumn 87, Issue 6, 2003, Pages 1189-1203

  Gomes, Marcelo P V ^a   Kaplan, Karen L ^b   Deitcher, Steven R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULANT THERAPY; BLEEDING; CANCER CHEMOTHERAPY; CASE REPORT; CAVOGRAPHY; CHEMOPROPHYLAXIS; CHRONOPHARMACOLOGY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; ECHOGRAPHY; HIGH RISK PATIENT; HUMAN; INFERIOR CAVA VEIN; INFERIOR CAVA VEIN FILTER; LUNG EMBOLISM; MALE; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; TESTIS CARCINOMA; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; VENA CAVA FILTER;

EID: 0344874281     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(03)00106-8     Document Type: Article

References (47)

1. Rogers FB, Strindberg G, Shackford SR, Osler TM, Morris CS, Ricci MA, et al. Five-year follow-up of prophylactic vena cava filters in high-risk trauma patients. Arch Surg 1998;133:406-11.
2. Jarrell BE, Posuniak E, Roberts J, Osterholm J, Cotler J, Ditunno J. A new method of management using the Kim-Ray Greenfield filter for deep venous thrombosis and pulmonary embolism in spinal cord injury. Surg Gynecol Obstet 1983;157:316-20.
3. Rodriguez JL, Lopez JM, Proctor MC, Conley JL, Gerndt SJ, Marx MV, et al. Early placement of prophylactic vena caval filters in injured patients at high risk for pulmonary embolism. J Trauma 1996;40:797-804.
4. Webb LX, Rush PT, Fuller SB, Meredith JW. Greenfield filter prophylaxis of pulmonary embolism in patients undergoing surgery for acetabular fracture. J Orthop Trauma 1992;6:139-54.
5. Streiff MB. Vena caval filters: a comprehensive review. Blood 2000;95:3669-77.
6. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409-15.
7. Greenfield LJ, Proctor MC. Recurrent thromboembolism in patients with vena cava filters. J Vasc Surg 2001;33:510-4.
8. Ballew KA, Philbrick JT, Becker DM. Vena cava filter devices. Clin Chest Med 1995;16:295-305.
9. Hye RJ, Mitchell AT, Dory CE, Freischlag JA, Roberts AC. Analysis of the transition to percutaneous placement of Greenfield filters. Arch Surg 1990;125:1550-3.
10. Mobin-Uddin K, McLean R, Jude JR. A new catheter technique of interruption of inferior vena cava for prevention of pulmonary embolism. Am Surg 1969;35:889-94.
11. Proctor MC. Indications for filter placement. Semin Vasc Surg 2000;13:194-8.
12. Girard P, Tardy B, Decousus H. Inferior vena cava interruption: how and when? Annu Rev Med 2000;51:1-15.
13. Greenfield LJ, Bruce TA, Nichols NB. Transvenous pulmonary embolectomy by catheter device. Ann Surg 1971;174:881-6.
14. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-93S.
15. Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters: indications, safety, effectiveness. Arch Intern Med 1992;152:1985-94.
16. Dorfman GS. Evaluating the roles and function of vena caval filters: will data be available before or after these devices are removed from the market? Radiology 1992;185:15-7.
17. Girard P, Stern JP, Parent F. Medical literature and vena cava filters: so far so weak. Chest 2002;122:963-7.
18. Guyatt G, Schunëmann H, Cook D, Jaeschke R, Pauker S. Bucher H. Grades of recommendation for antithrombotic agents. Chest 2001;119:3S-7S.
19. Alexander JJ, Yuhas JP, Piotrowski JJ. Is the increasing use of prophylactic percutaneous IVC filters justified? Am J Surg 1994:168:102-6.
20. Greenfield LJ, Rutherford RB, and the participants of the Vena Caval Filter Consensus Conference. Recommended reporting standards for vena caval filter placement and patient follow-up. J Vasc Interv Radiol 1999;10:1013-9.
21. Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999;159:2029-32.
22. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. Arch Intern Med 1997;157:2317-21.
23. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
24. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 1993:119:874-81.
25. Hull RD, Pineo GF. Low-molecular-weight heparin in the treatment of venous thromboembolism. Semin Thromb Hemost 2000;26(suppl 1):61-7.
26. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-77.
27. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once of twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202.
28. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S.
29. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7.
30. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-11.
31. Hutten B, Prins MH, Gent M, Ginsberg JS. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-83.
32. Bona RD, Sivjee KY. Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995;74:1055-8.
33. Blebea J, Wilson R, Waybill P, et al. Deep venous thrombosis after percutaneous insertion of vena caval filters. J Vasc Surg 1999;30:821-9.
34. Brandjes DPM, Buller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349:759-62.
35. Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: is there still and indication? Thromb Haemost 2001;86:499-508.
36. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
37. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74.
38. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000;51:169-85.
39. Eichinger S, Stümpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-9.
40. Greenfield LJ, Proctor MC. The percutaneous Greenfield filter: outcomes and practice patterns. J Vasc Surg 2000;32:888-93.
41. Hull RD, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-8.
42. Crochet DP, Brunel P, Trogrlic S, Grossetête R, Auget JL, Dary C. Long-term follow-up of Vena-Tech LGM filter: predictors and frequency of caval occlusion. J Vasc Interv Radiol 1999;10:137-42.
43. Greenfield LJ, Proctor MC. Twenty-year clinical experience with the Greenfield filter. Cardiovasc Surg 1995;3:199-205.
44. Nicholson AA, Ettles DF, Paddon AJ, Dyet JF. Long-term follow-up of the Bird's Nest IVC filter. Clin Radiol 1999;54:759-64.
45. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-9.
46. Schulman S, Granqvist S, Holmström M, et al. The duration of anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8.
47. Goldhaber SZ. A free-floating approach to filters. Arch Intern Med 1997;157:264-5.